Aligos Therapeutics Inc (ALGS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.51-10.16%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ALGS
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | 2.2 | 3.6 | 6.2 | 0.0 | 0.0 | 0.0 |
| Operating Expenses & Income | |||||||
| R&D Expenses | 88.4 | 69.5 | 70.3 | 73.0 | 85.1 | 104.2 | 79.9 |
| Other Operating Expenses, Total | 2.9 | 3.9 | 4.4 | 3.4 | 1.6 | 0.1 | (10.5) |
| Operating Income | (79.0) | (88.0) | (89.2) | (88.1) | (97.6) | (128.3) | (97.8) |
| Earnings from Continuing Operations | |||||||
| EBT, Incl. Unusual Items | (72.7) | (23.9) | (130.9) | (86.9) | (95.9) | (128.2) | (108.4) |
| Income Tax Expense | 3.2 | 0.3 | 0.3 | 0.8 | 0.1 | 0.1 | 0.2 |
| Net Income | |||||||
| Net Income | (76.0) | (24.2) | (131.2) | (87.7) | (96.0) | (128.3) | (108.5) |
| Per Share | |||||||
| Basic EPS | (7.28) | (2.45) | (20.94) | (34.20) | (2.25) | — | — |
| Diluted EPS | (7.28) | (2.45) | (20.94) | (34.20) | (2.25) | — | — |
| Basic Weighted Avg Shares | 10.4 | 9.9 | 6.3 | 2.6 | 42.7 | — | — |
| Diluted Weighted Avg Shares | 10.4 | 9.9 | 6.3 | 2.6 | 42.7 | — | — |
| Supplemental | |||||||
| EBIT | (79.0) | (88.0) | (89.2) | (88.1) | (97.6) | (128.3) | (97.8) |
| Effective Tax Rate | -4.4% | — | — | -0.9% | -0.1% | -0.1% | -0.1% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.